

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Link-Asia International MedTech Group Limited

環亞國際醫療科技集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 1143)

VOLUNTARY ANNOUNCEMENT POTENTIAL CONNECTED TRANSACTION FORMATION OF A JOINT VENTURE COMPANY

This announcement is made by Link-Asia International MedTech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business development of the Group.

FORMATION OF A JOINT VENTURE COMPANY

The board of directors of the Company is pleased to announce that after trading hours on 22 March 2023, the Company, through its wholly-owned subsidiary, Huashi Management Consulting (Shenzhen) Limited (華氏管理諮詢(深圳)有限公司, “**Huashi**”), entered into a formal joint venture agreement (the “**Joint Venture Agreement**”) with Yuanda Chinese Medicine Chain (Shenzhen) Company Limited (元大中醫連鎖(深圳)有限公司, “**Yuanda**”) and Mr. Liu Zhiwei (“**Mr. Liu**”), an executive director of the Company. Pursuant to the Joint Venture Agreement, (i) Huashi, Yuanda and Mr. Liu would hold 51%, 39% and 10% of the shares of the Joint Venture Company, respectively; and (ii) the Joint Venture Company is principally engaged in the business of Chinese medicine healthcare services, health and wellness consultation and brand management, as well as corporate consulting.

Mr. Liu is an executive director of the Company, and Mr. Liu and his wife directly and indirectly hold approximately 100% equity interest in Yuanda, therefore Mr. Liu and Yuanda are the connected persons of the Company. Accordingly, the entering into of the Joint Venture Agreement and the formation of the Joint Venture Company thereunder by the parties will constitute connected transactions for the Company.

As one or more of the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) for entering into the Joint Venture Agreement is less than 5% and the total consideration is less than HK\$3,000,000, it is expected to be exempted from the shareholders’ approval, annual review and all disclosure requirements under Rule 14A.76(1)(c) of the Listing Rules.

INFORMATION ON THE JOINT VENTURE COMPANY

(1) Scope of business of the Joint Venture Company

The scope of business of the Joint Venture Company includes: brand management; corporate consulting; health and wellness consulting services; Chinese medicine health and wellness services; sales of health care products; sales of health food (pre-packaged); offsite health management services; technology services, technology development, technology consulting, technology exchange, technology transfer, technology promotion; information consulting services (excluding licensed information consulting services); marketing; software development; data processing services; conference and exhibition services; etiquette services; software outsourcing services, etc.

(2) Operation term of the Joint Venture Company

30 years from the date of obtaining the business license, in accordance with the Company Law of the People's Republic of China and other relevant regulations.

(3) Shareholder Capital Injection

The total capital injection amount of all shareholders to the Joint Venture Company shall be RMB2,000,000 (subject to the actual amount of final paid-up capital). The amount of capital injection to be paid in cash by each shareholder is as follows:

Name of shareholders	Capital Injection Amount (RMB'000)	Shareholding Percentage
Huashi Management Consulting (Shenzhen) Limited	1,020	51%
Yuanda Chinese Medicine Chain (Shenzhen) Company Limited	780	39%
Mr. Liu Zhiwei	200	10%
Total	2,000	100%

As at the date of this announcement, the above matter has been approved by the board of directors of the Company, and Mr. Liu Zhiwei (as a director of the Company and a shareholder and director of Yuanda) has abstained from voting on the resolution of the board of directors of the Company to approve the above transaction. Completion is subject to the final signing process of the Joint Venture Agreement by the parties.

The board of directors believes that the formation of the Joint Venture Company will facilitate the expansion of the Company's healthcare business chain, and the Joint Venture Company is expected to contribute to the revenue and profit of the Company, which in turn will enhance the financial performance of the Company. The board of directors considers that the Joint Venture Agreement is still on normal commercial terms and its terms are fair and reasonable, and the transactions contemplated thereunder are in the interests of the Company and the Shareholders as a whole.

GENERAL INFORMATION

Shareholders and potential investor of the Company should be noted that the Joint Venture Company is still in the establishment stage and has not yet completed its business registration, and the implementation and progress are subject to certain uncertainties. Further announcement(s) will be made by the Company as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

By Order of the Board
Link-Asia International MedTech Group Limited
Lin Dailian
Chairman and executive Director

Hong Kong, 22 March 2023

As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Wang Guozhen, Mr. Liu Zhiwei, Mr. Li Yinxiang and Ms. Lin Xiaoshan as executive Directors; Mr. Li Huiwu, Mr. Yang Weidong and Mr. Chak Chi Shing as independent non-executive Directors.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.